Story updated at 9:55 a.m. to reflect market activity.
Shares of Edwards Lidfesciences (EW) gained 0.9% to $98.46 in morning trading.
The analyst firm also raised its revenue and EPS estimates for the company through 2015. Edwards Lifesciences' recent results suggest that global TAVI market growth may accelerate according to JMP analyst J.T. Haresco.
"Our own channel checks in Europe suggest that the large number of four- and five-year follow-up visits in the last six months may have had a positive impact on physician adoption by increasing their level of confidence in the technology," Haresco wrote. "In addition, we believe that longer-term data being presented at the upcoming TCT conference may serve as a near-term driver for the stock."
Separately, TheStreet Ratings team rates EDWARDS LIFESCIENCES CORP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate EDWARDS LIFESCIENCES CORP (EW) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."